Roche is foraying into artificial intelligence through a suite of partnering and M&A deals that are causing it to reinvent its due diligence process. The pharma is aiming to separate fact from fiction, and accurately assess technologies that lie beyond its core expertise in drug development.
In the last two months, Roche has signed three deals with data and analytics or AI companies aimed at rapidly expanding its precision medicine capabilities.
The deals are part of the pharma’s inroads into digital health that build on its 2015 partnership with Foundation Medicine Inc., which accessed the genomics company’s cancer molecular profiling database.
On Feb. 16, Roche announced plans to acquire all outstanding shares of Flatiron Health Inc. The pharma already held a 13% stake after leading the company’s